Oral and Oropharyngeal mucositis
Oral and oropharyngeal mucositis occurs in 52-80% of children undergoing treatment for cancer. 1 Mucositis is a debilitating condition which can be so severe it can delay or stop oncology treatment. The mucositis disease process is initiated by chemotherapy or radiotherapy at 0-2 days, followed by cell damage at 2-10 days. Frank ulceration and mucosal damage occurs at 10-15 days and finally healing after 2-3 weeks. The clinical presentation is a combination of erythema and ulceration; and as healing begins, mucosal sloughing affects the intra-oral tissues and oesophageal tract. Maintaining adequate oral hygiene is difficult due to oral discomfort which may further exacerbate the condition and increase a patient's vulnerability to developing infection. The consequences for paediatric patients are significant; eating, drinking, speaking and engaging with those around them can be significantly restricted which presents concerns regarding recovery and physical and mental wellbeing. Psychological distress has been described by parents of children suffering from mucositis at a time when stress and anxiety of the parent and child is already amplified by many other factors. Mucositis can be graded using the 'World Health Organisation (WHO) Grading,' which comprises gradings zero to four 3 , as can be seen in the The patient cannot swallow a solid diet;
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Mucositis is so severe that alimentation is not possible
Management of mucositis
General management of mucositis often involves a mixture of preventive and symptomatic control measures such as; oral hygiene instruction, soft diet, cryotherapy, protective gels, analgesics ranging from paracetamol and non-steroidal analgesia to narcotic analgesia, topical anaesthetics, benzydamine hydrochloride sprays or mouthwashes and chlorhexidine and calcium phosphate mouthrinses. Many of these, for example mouthwashes, require a certain degree of cooperation and maturity which not all paediatric patients will have. Mucositis is such a common and significant problem in oncology that many different guidelines have been developed to assist practitioners. opening. 12 There has also been research involving orthodontic patients concerning the potential for LLLT to accelerate tooth movement and also reduce orthodontic related pain 13, 14 .
WHO Mucositis Grading

Low Level Light therapy
Low Level Light therapy and mucositis
In the literature there have been many studies involving LLLT as a treatment modality for oral and oro-pharyngeal mucositis. In a systematic review with meta-analysis by Bjordal et al, 15 Low Level Light Therapy was shown to reduce pain, severity and duration of mucositis. This paper included 11 randomised placebo controlled trials with a total of 415 patients. The relative risk of developing mucositis was found to be significantly reduced after LLLT when compared to placebo (RR = 2.03 p value = 0.02). In patients with mucositis, the number of days patients had mucositis was found to be reduced for severity gradings 2 or more from 4.38 days to 1.33 days compared with placebo. The benefits that LLLT can offer to the paediatric patient appear to be significant. As this is often a patient group where cooperation may be limited, quick, efficient and effective treatment is necessary. In addition paediatric oncology patients in particular are a group where the prevention of infection and pain are of paramount importance.
Low Level Light therapy use for paediatric patient in Glasgow
Currently in the Royal Hospital for Children (previously The Royal Hospital for Sick Children) in Glasgow, LLLT is used daily in the management of oro-pharyngeal mucositis by the Paediatric Dentistry department. It is used often in conjunction with previously described measures such as mouth rinses, analgesia and protective gels. The paediatric dental team makes regular visits to the oncology ward and has a good relationship with the ward staff allowing a team approach to the provision of LLLT. LLLT is delivered using a Diobeam 830 laser (830nm) with an output of 150mW (see Figure 2 ). Bensadoun at al 2015 17 recommended that wavelengths of 633-685nm or 780-830 nm and power output between 10 and 150 mW are used to treat mucositis. Initially an extra-and intra-oral examination by a qualified dentist determines the areas affected by mucositis and a WHO mucositis grading is assigned. An administered dose (J/cm2) is then delivered according to the severity of mucositis. 3 The paperwork completed for each treatment episode used can be seen below in Figure 3 . Although in Glasgow the' laser' is primarily used for symptomatic mucositis, one joule setting per centimetre squared is available for use on healthy mucosa, which would allow for the laser to be given as prophylactic treatment. The Diobeam laser is classed as a 3B laser which means it carries an ocular hazard. Local laser safety precautions are employed, such as using safety glasses to protect the patient, parent's and user's eyes. The laser is used in an approved room which has blinds on the windows, a locked door and safety signs displayed outside. LLLT is not visible but has a red guide light to help the user to visualise the target area and an auditory guide for when the laser is active. Treatment is painless.
Similar to radiographic regulations, there are also local laser rules which have to be followed and training must be completed prior to any clinician delivering treatment. The results are summarised in the Tables 1-4 below. The most common WHO grade for mucositis was Grade 3 (extensive erythema and ulceration and cannot swallow a solid diet). A statistically significant change in pain score was noted with the median change of pain score being 2 (P-value <0.0005). No statistically significant relationship between neutrophil count and pain response was found (P-value = 0.263), or indeed between pain response and type of tumour (blood/solid) (P-value = 0.121).
Results
Summary of malignancies of the 39 patients included in the study
WHO Gradings pre-LLLT of the 319 episodes of treatment analysed For example: 8/10 pain score pre-treatment to 6/10 post-treatment 
Pain Response versus Type of tumour
No statistical relationship between pain response and type of tumour, whether blood borne or solid tumour. (P-value = 0.121) Parents, staff and patients have embraced LLLT, finding it easy and beneficial, with regular requests for treatment and many positive reports. The ward and dental team work closely to ensure LLLT is available to those patients who need it and it has been widely accepted by the medical team as an effective management tool for mucositis.
Currently in Glasgow, due to resources and staff availability, LLLT is mainly provided when patients develop symptomatic mucositis. Our research has shown the ability to reduce pain in this patient group and this theoretically should reduce the need for narcotic analgesia and allow patients to maintain oral diets. This has been supported with one of the pain nurses in Glasgow stating that, 'The laser provides better pain relief than ketamine.' A patient explained when asked about LLLT 'my mouth was a 10/10, now it's a 0/10.' Figueiredo et al in 2013 18 conducted a meta-analysis of the prophylactic use of LLLT to prevent mucositis and showed a significant positive effect. This research may extend our provision of LLLT, utilizing the lowest setting on the laser to provide this.
Conclusion
As with all new technologies, availability and cost naturally become less of a consideration over time. Access to LLLT across medical and dental services will no doubt improve, alongside cost effectiveness. A study by Bezinelli et al (2014) has already demonstrated that oncology patients with mucositis not treated with LLLT had 30% higher hospitalisation costs, 19 an important finding for NHS hospitals under mounting financial pressures.
Provision of LLLT is straightforward, quick and effective for many conditions. LLLT use within the specialist dental services continues to expand throughout the UK transforming the care
we are able to routinely provide. Its use is also expanding in other areas of dental health and it will be interesting to see what the future holds for this remarkable technology. Tables 2 and 3 Graphs taken from statistical report by Johnathan Love B.Sc. 'Investigating the low level light therapy in paediatric patients suffering from chemotherapy induced oropharyngeal mucositis.'
